In short
Pancreatic neuroendocrine tumors that have spread beyond the pancreas represent a complex and challenging form of cancer that behaves very differently from the more common types of pancreatic disease. Understanding what happens when this rare cancer spreads, how it affects daily life, and what families can expect helps patients and their loved ones navigate this difficult journey with greater confidence and support.
Key points
- Metastatic pancreatic neuroendocrine tumors behave very differently from common pancreatic cancer, often growing slowly and allowing patients to live for years even after spreading
- The five-year survival rate for metastatic pancreatic neuroendocrine tumors is about 23%, but this varies greatly based on tumor grade and individual characteristics
- Well-differentiated tumors with low Ki67 proliferation index tend to be more indolent and have better outcomes than poorly differentiated, high-grade tumors
- Without treatment, these tumors continue growing and spreading, with the liver being the most common site of metastasis, though bones, spleen, and other organs can be affected
- Multiple treatment options exist including surgery, hormone therapy, targeted drugs like cabozantinib, chemotherapy, and specialized therapies like PRRT and liver-directed treatments
- Daily life impacts include fatigue, digestive symptoms, pain, work modifications, and emotional challenges, but many patients find ways to maintain meaningful activities and quality of life
- Clinical trials offer access to promising new treatments, and family support in finding and participating in trials can be valuable for patients with this rare disease
- Liver transplantation is a unique option for metastatic neuroendocrine tumors that is not typically available for other types of metastatic cancer
Understanding Your Outlook When Cancer Has Spread
When doctors talk about prognosis, they mean the likely course your disease will take and your chances of recovery. With pancreatic neuroendocrine tumors that have spread to other parts of the body, the outlook varies considerably depending on several important factors. These tumors behave quite differently from the more common pancreatic adenocarcinoma, which tends to grow and spread much more rapidly.
Pancreatic neuroendocrine tumors are generally described as having a better overall prognosis than pancreatic adenocarcinoma. However, when these tumors have already metastasized—meaning they have spread to distant organs like the liver, bones, or spleen—the situation becomes more serious. The five-year relative survival rate for pancreatic neuroendocrine tumors that have spread is around 23%, which highlights both the serious nature of advanced disease and the ongoing need for new treatment approaches.
Despite these statistics, it's important to understand that pancreatic neuroendocrine tumors often show a more indolent, or slow-growing, behavior compared to other malignancies. This means that even with metastatic disease, many patients can live for years with appropriate treatment and management. Some patients continue to maintain good quality of life and remain active for extended periods, especially when their tumors are well-differentiated, meaning the cancer cells still look somewhat like normal cells under the microscope.
The grade of the tumor plays a crucial role in determining prognosis. Well-differentiated tumors with low grade tend to be slower growing, while poorly differentiated and high-grade tumors have the potential to behave more aggressively. Intermediate-grade neuroendocrine tumors have a slightly worse prognosis than low-grade tumors. The Ki67 proliferation index, a measure of how quickly cancer cells are dividing, helps doctors understand how aggressive your particular tumor might be.
How the Disease Progresses Without Treatment
When pancreatic neuroendocrine tumors are left untreated, they continue to grow and spread, though often at a slower pace than other types of pancreatic cancer. The natural progression of these tumors depends heavily on whether they are functional or nonfunctional, and how well or poorly differentiated they are.
Functional tumors produce excess amounts of hormones like insulin, gastrin, or glucagon, which create symptoms related to those specific hormones. Without treatment, these hormone-related symptoms worsen over time. For example, a gastrinoma that produces too much gastrin causes increasingly severe stomach ulcers and diarrhea. An insulinoma that makes too much insulin leads to more frequent and dangerous episodes of low blood sugar.
Nonfunctional tumors, which make up the majority of pancreatic neuroendocrine tumors, don't produce excess hormones and therefore don't cause hormone-related symptoms early on. These tumors are often quite large when first discovered because they grow silently for years without causing noticeable problems. By the time they're found, they have frequently already spread to the liver or other organs. Without treatment, these tumors continue to enlarge and spread to additional sites in the body.
As metastatic pancreatic neuroendocrine tumors progress, the liver becomes the most common site of spread, though tumors can also travel to the bones, spleen, and other distant organs. One documented case described a patient with an aggressive pancreatic neuroendocrine tumor that spread to the liver, spleen, and spine, causing progressive symptoms and deterioration over time.
The speed of progression varies dramatically. Some patients with well-differentiated tumors experience very slow progression over many years, with the tumor burden increasing gradually. Others with poorly differentiated tumors face rapid growth and spread, with the disease behaving more like small-cell carcinoma of the lung—an extremely aggressive cancer type.
Physical symptoms develop as the tumor grows and spreads. Patients may experience increasing fatigue, weight loss, and pain in the abdomen or back as the pancreatic mass enlarges. When liver metastases become extensive, they can cause the liver to swell, leading to abdominal distension, loss of appetite, and eventually jaundice—a yellowing of the skin and eyes that indicates the liver is struggling to function properly.
Possible Complications and Unexpected Developments
Metastatic pancreatic neuroendocrine tumors can lead to various complications that affect different organ systems and significantly impact a patient's health. Understanding these potential complications helps patients and families recognize warning signs and seek timely medical attention.
One serious complication is carcinoid syndrome, which occurs when functional tumors release large amounts of hormones and other substances into the bloodstream. This syndrome causes symptoms including flushing of the skin, severe diarrhea, wheezing, and rapid heartbeat. In severe cases, patients can experience a life-threatening condition called carcinoid crisis, characterized by extremely low blood pressure, confusion, and difficulty breathing.
When tumors produce too much insulin, patients face the dangerous complication of severe hypoglycemia—extremely low blood sugar. This can cause confusion, shakiness, seizures, loss of consciousness, and if not treated promptly, can lead to permanent brain damage or death. These episodes may become more frequent and severe as the tumor grows.
Liver metastases can overwhelm the liver's ability to function properly. As cancer takes over more and more liver tissue, the organ cannot effectively filter toxins from the blood, produce essential proteins, or manage blood sugar levels. This leads to symptoms including jaundice, fluid accumulation in the abdomen, easy bruising and bleeding, and confusion from toxin buildup in the brain.
Bone metastases cause pain, increase the risk of fractures, and can compress the spinal cord. One case report described a patient who developed metastasis within the T10 vertebra in the spine, requiring radiotherapy to prevent further complications. Bone complications can severely limit mobility and independence.
Nutritional complications are common because the pancreas plays a vital role in digestion. When tumors affect pancreatic function or when treatments impact the digestive system, patients may struggle to absorb nutrients properly. This leads to weight loss, vitamin deficiencies, and overall weakness. Some patients develop diarrhea that's difficult to control, leading to dehydration and electrolyte imbalances.
Pancreatic neuroendocrine tumors can also cause obstruction of the bile duct, leading to cholestasis—a backup of bile that causes severe itching, jaundice, and increases the risk of infections in the bile ducts. Similarly, tumors can block the pancreatic duct or parts of the digestive tract, causing pain and digestive problems.
Patients receiving various treatments face specific complications related to those therapies. Chemotherapy can suppress the immune system, increasing infection risk and causing fatigue, nausea, and changes in blood cell counts. Hormone therapies may cause side effects related to hormone imbalances. Some treatments affect heart function, while others can impact kidney function or cause allergic reactions.
Impact on Daily Life and Activities
Living with metastatic pancreatic neuroendocrine tumor profoundly affects many aspects of daily life, from physical abilities to emotional well-being, work responsibilities, and social relationships. Each patient's experience is unique, but many face similar challenges that require adaptation and support.
Physical limitations often develop gradually or suddenly, depending on the tumor's behavior and location of metastases. Many patients experience persistent fatigue that makes even simple tasks feel exhausting. Activities that once seemed effortless—climbing stairs, carrying groceries, or walking moderate distances—may become difficult or impossible. One patient described struggling to walk up the stairs to her condo and being unable to take more than a few bites of food as her liver became enlarged with tumors.
Digestive symptoms significantly disrupt daily routines. Chronic diarrhea, a common symptom especially with functional tumors, requires constant access to bathroom facilities and can make leaving home anxiety-provoking. Nausea and changes in appetite affect meal planning and social eating situations. Some patients find they can only tolerate small, frequent meals rather than normal-sized portions. Weight loss may lead to clothing not fitting properly and concerns about appearance.
Pain management becomes a daily priority for many patients. Abdominal pain, back pain, or bone pain from metastases may require regular medication and lifestyle adjustments. Pain can interfere with sleep, making fatigue worse and affecting mood and cognitive function. Finding comfortable positions for sleeping, sitting, or moving becomes an ongoing challenge.
Work life often requires significant modifications or may become impossible to continue. Frequent medical appointments for scans, blood tests, and treatments take time away from work. Fatigue and symptoms make it difficult to maintain focus and productivity. Some patients must reduce their hours, change to less demanding positions, or stop working entirely. This transition can affect financial security and sense of identity and purpose. However, some patients do continue working and teaching, finding that maintaining professional engagement provides meaning and normalcy.
Social relationships undergo changes as the disease progresses. Friends and family members may not understand the unpredictable nature of symptoms or the exhaustion that comes with cancer and its treatment. Social activities that involve food, physical activity, or being away from home for extended periods become challenging. Some patients feel isolated because others don't know how to offer support or are uncomfortable discussing cancer.
Hobbies and recreational activities may need adaptation. However, many patients find ways to continue enjoying meaningful activities. One patient continued to go canoeing with her sister and exercised at the gym despite her diagnosis. Another patient traveled and maintained an active lifestyle even while managing multiple tumors. Finding activities that bring joy and can be modified as needed helps maintain quality of life.
Emotional and mental health impacts are substantial. Anxiety about scan results, disease progression, and the future is common. Some patients experience depression, especially when facing multiple setbacks or dealing with poorly controlled symptoms. The uncertainty of living with a chronic, life-threatening illness creates ongoing stress. One patient described it as "this balance of feeling good—like 'I don't have cancer'—but in the back of my mind, I wonder when this is going to become a problem."
Coping strategies that help patients manage these impacts include maintaining realistic but positive attitudes, staying engaged with healthcare teams, connecting with others who have similar diagnoses, and focusing on what can be controlled. Some patients practice mental hygiene by staying active and engaged through teaching, exercise, and hobbies. Others find meaning in planning for the future and setting achievable goals despite their diagnosis.
Supporting Your Family Member Through Clinical Trials
Clinical trials represent an important opportunity for patients with metastatic pancreatic neuroendocrine tumors to access new treatments that may not yet be widely available. Family members play a crucial role in helping patients learn about, decide on, and participate in these research studies. Understanding how clinical trials work and how to provide effective support can make a significant difference in the patient's journey.
Clinical trials for pancreatic neuroendocrine tumors test new medications, combinations of existing treatments, different doses or schedules, and novel approaches like targeted therapies. These studies are carefully designed to answer specific questions about safety and effectiveness while protecting patient welfare. Recent approvals of new treatments for pancreatic neuroendocrine tumors, such as cabozantinib (CABOMETYX), came directly from clinical trial research.
Families can help by researching available clinical trials together with the patient. Many resources exist online, including the National Cancer Institute's database and hospital-specific trial listings. However, the information can be overwhelming and technical. Family members can assist by organizing information, making lists of questions, and helping compare different trial options. It's helpful to create a spreadsheet or document that tracks trial names, locations, eligibility requirements, and key details about what each study involves.
Understanding eligibility is crucial. Clinical trials have specific requirements about the type and stage of cancer, previous treatments received, overall health status, and other factors. Family members can help gather medical records, treatment histories, and test results that the research team will need to determine if the patient qualifies. This administrative support reduces stress on the patient who may already feel overwhelmed by their diagnosis and symptoms.
The decision to join a clinical trial is deeply personal and should never be rushed. Families can support decision-making by attending appointments where trials are discussed, taking notes, and asking clarifying questions that the patient might not think of in the moment. Important questions include: What is the goal of this trial? What treatments will be involved? What are the possible side effects? How often will visits be required? Will there be any costs not covered by insurance? What happens if the disease progresses during the trial?
Practical support becomes essential once a patient enrolls in a trial. Clinical trials often require frequent visits for monitoring, additional tests and scans, and careful tracking of symptoms and side effects. Family members can help by providing transportation to appointments, keeping a calendar of visit schedules, organizing medications and supplements, and maintaining a symptom diary. Some trials have specific requirements about diet, activities, or other medications that must be avoided, and family support in following these rules is valuable.
Emotional support throughout the trial is equally important. Patients may feel anxious about whether the new treatment will work, frustrated by additional testing requirements, or discouraged if early results aren't as hoped. Family members can provide encouragement, help maintain perspective, and remind the patient that participating in research contributes to advancing knowledge that helps future patients—even if the personal benefit is uncertain.
Communication with the research team should be open and ongoing. Family members can help ensure that all side effects and changes in condition are reported promptly. If concerns arise about the trial, families can encourage and facilitate conversations with the study doctors and nurses. It's important to remember that patients can withdraw from a clinical trial at any time for any reason, and family support for this decision is important if the patient feels participation is no longer right for them.
Financial considerations of trial participation deserve attention. While the experimental treatment itself is typically provided at no cost, there may be expenses related to additional testing, travel to the trial site, or time away from work. Some trials offer assistance with travel and lodging. Family members can help investigate what financial support might be available and plan for these potential costs.
Finding the right clinical trial may require looking beyond local hospitals. Some of the most innovative trials for pancreatic neuroendocrine tumors are conducted at specialized cancer centers with expertise in this rare disease. One patient described traveling from Indiana to New York to see a specialist known for expertise in neuroendocrine tumors and accessing more treatment options than were available locally. Families can support this process by helping research distant centers, plan travel logistics, and coordinate care between local and specialized teams.
Registered drugs used for this disease
List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:
- Lanreotide (Sandostatin LAR) – A somatostatin analog given as monthly injections that blocks the growth hormone that feeds slow-developing neuroendocrine tumors
- Cabozantinib (CABOMETYX) – A targeted therapy approved for adults with well-differentiated pancreatic neuroendocrine tumors who have received previous treatment, are ineligible for surgery, and whose cancer has progressed
- Oxaliplatin – A chemotherapy drug used in combination regimens for treatment of metastatic pancreatic neuroendocrine tumors
- Capecitabine – A chemotherapy drug used in combination regimens (often with oxaliplatin in CAPTEM protocols) for treatment of metastatic pancreatic neuroendocrine tumors
